Transmembrane Glycoprotein Ligand

Atigotatug (BMS-986012) is a fully human IgG1 antibody binds specifically to FucGM1 with an EC₅₀ of 0.15 nmol/L for FucGM1. Atigotatug is a FcγRIIIa ligand with a K_d of 21 nmol/L. Atigotatug demonstrates antitumor efficacy in multiple mouse small cell lung cancer models.

CP05 is a peptide that specifically recognizes an exosome surface marker (CD63). CP05 anchors exosomes to target tissues for in vivo delivery of exosomes.

AD 01, a 24 amino acid peptide of FKBPL (FK506-binding protein like), possesses potent anti-angiogenic activity. AD 01 bind to the CD44 receptor and inhibit tumour cell migration in a CD44 dependant manner.

VCAM1 binding peptide acetate is a VCAM1 binder with internalization activity. VCAM1 binding peptide acetate can be labeled with 5-FAM. VCAM1 binding peptide acetate serves as a component of biosensing systems for visualizing in vitro VCAM1 endocytic pathways. VCAM1 binding peptide acetate forms the research and development basis for MacroP and NAMP, PET radiotracers targeting VCAM1. VCAM1 binding peptide acetate is applicable to studies related to atherosclerosis.

CD63-1 aptamer sodium is a high-affinity and specific DNA aptamer targeting the CD63 protein (K_d = 38.71 nM). CD63-1 aptamer sodium effectively binds to CD63-positive cells and serves as an exosome isolation reagent. CD63-1 aptamer sodium is applicable to breast cancer-related research.

SYL3C aptamer sodium is a DNA aptamer targeting EpCAM. SYL3C aptamer sodium targets a variety of cancer cell lines. SYL3C aptamer sodium can be used for targeted cancer cell imaging and circulating tumor cell detection.

VCAM1 binding peptide, FITC labeled acetate is a FITC-labeled VCAM1 binding peptide acetate (HY-P11088A). VCAM1 binding peptide acetate is a VCAM1 binder with internalization activity. VCAM1 binding peptide acetate serves as a component of biosensing systems for visualizing in vitro VCAM1 endocytic pathways. VCAM1 binding peptide acetate forms the research and development basis for MacroP and NAMP, PET radiotracers targeting VCAM1. VCAM1 binding peptide acetate is applicable to studies related to atherosclerosis.

EP 80317 is a selective CD36 ligand. EP 80317 protects the heart against damage and dysfunction elicited by myocardial ischaemia and reperfusion (MI/R), along with a transient reduction in peripheral lipolysis. EP 80317 can be used for the study of cardiovascular disease.

KDdiA-PC is one of the most potent CD36 ligands in oxidized LDL (oxLDL).

cLABL is a cyclic peptide that specifically binds to ICAM‑1. cLABL mediates targeted enrichment and rapid endocytosis of nanoparticles. cLABL is applicable to researches such as precise drug delivery at inflammatory sites.

EP 80317 acetate is a selective CD36 ligand. EP 80317 acetate protects the heart against damage and dysfunction elicited by myocardial ischaemia and reperfusion (MI/R), along with a transient reduction in peripheral lipolysis. EP 80317 acetate can be used for the study of cardiovascular disease.

VHPKQHR is a peptide-based delivery enhancer that binds to VCAM-1. VHPKQHR enables intracellular internalization of relevant nanomaterials and facilitates the targeted delivery of miRNA inhibitors to inflamed endothelial cells and endothelial cells activated by disturbed flow. When conjugated with magnetic mesoporous silica nanoparticles, VHPKQHR achieves targeted accumulation at atherosclerotic plaque sites. When displayed on the surface of polyelectrolyte complex micelles, VHPKQHR enhances the relevant effects of anti-miR-92a in Apoe^-/- mice. When conjugated with ultrasmall superparamagnetic iron oxide nanoparticles, VHPKQHR forms a contrast agent for T₁-weighted magnetic resonance imaging. VHPKQHR can be used in research related to atherosclerosis, stenosis and rheumatoid arthritis.

Pep2 Peptide (also known as scavenger receptor B2) is a peptide ligand for the transmembrane glycoprotein CD36. Pep2 Peptide selectively binds to CD36 over HAS, IgG and CD44. Pep2 Peptide can be studied in research on enhancing delivery of anticancer agent.

VCAM1 binding peptide is a VCAM1 binder with internalization activity. VCAM1 binding peptide can be labeled with 5-FAM. VCAM1 binding peptide serves as a component of biosensing systems for visualizing in vitro VCAM1 endocytic pathways. VCAM1 binding peptide forms the research and development basis for MacroP and NAMP, PET radiotracers targeting VCAM1. VCAM1 binding peptide is applicable to studies related to atherosclerosis.

(E/Z)-Sulfosuccinimidyl oleate sodium is the racemate of (E)-Sulfosuccinimidyl oleate sodium and (Z)-Sulfosuccinimidyl oleate sodium. Sulfosuccinimidyl oleate sodium (Sulfo-N-succinimidyl oleate sodium) is a long-chain fatty acid that inhibits fatty acid transport into cells. Sulfosuccinimidyl oleate sodium is a potent and irreversible inhibitor of the mitochondrial respiratory chain. Sulfosuccinimidyl oleate sodium binds to the CD36 receptor on the surface of microglial cells. Sulfosuccinimidyl oleate sodium exhibits anti-inflammatory effects.

SYL3C aptamer sodium scrambled negative control is the sequence scrambled negative control of SYL3C aptamer sodium.